Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
10.3389/fpubh.2024.1277113 5 ChongB.JayabaskaranJ.KongG.ChanY
In-depth, scientific discussion is much harder
If you seek clinical depth and personalization without the brand premium, Zealthy's model aligns more closely with precision medicine, as does PlexusDx with the added option of genetic context
Clark 5 , David Liebeskind 6 , Ryan McTaggart 7 1 Revalesio, Tacoma, United States, 2 Northwestern University, Feinberg School of Medicine, Chicago, United States, 3 University of Pennsylvania, Philadelphia, United States, 4 Houston Methodist Hospital, Houston, United States, 5 Oregon Stroke Ctr at OHSU, Portland, United States, 6 University of California Los Angeles, Los Angeles, United States, 7 Rhode Island Hospital, Brown University, Providence, United States Background and Aims: RNS60, an experimental cytoprotective drug, showed preliminary signs of efficacy in the proof-of-concept Phase 2 RESCUE trial in participants with acute ischemic stroke 6), early antiplatelet use was associated with improved functional outcomes on mRS (0.85, 0.76-0.95) and less 7-day NIHSS deterioration (0.63, 0.41-0.98)
Our experts will work with you to develop a sustainable plan that balances efficacy and affordability
US$ 23.50
US$ 23.10
US$ 24.70
US$ 24.52
US$ 29.46
US$ 24.29
US$ 21.20
US$ 29.29
US$ 24.18
